ReviewPathogens & immunity2022
Update on the Pathogenesis, Virulence, and Treatment of
Review in Pathogens & immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 58 citations in OpenAlex.
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Clinical characteristics, healthcare-associated exposures, and antifungal susceptibility patterns of Candida auris colonization and invasive infections: a retrospective observational study at a single center in Turkey.BMC infectious diseases · 2026Observational
- Candida auris: a multidimensional focus on its identification, epidemiology, pathogenesis, and therapeutic options.Archives of microbiology · 2026Review
- UnderstandingJournal of medical microbiology · 2026Review
- Biocide Response of Candida auris.Mycoses · 2026Review
- Avian Candidiasis: A Comprehensive Review of Pathogenesis, Diagnosis, and Control.Veterinary sciences · 2026Review
- Genomic characterization of antifungal resistance patterns in Candida auris clade I: A large-scale analysis of 647 global genomes.Northern clinics of Istanbul · 2026Article
- Repositioning Antimicrobial Peptides Against WHO-Priority Fungi.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Epidemiological and microbiological characterization of Candidozyma auris (Candida auris) isolates from a tertiary hospital in Cairo, Egypt: an 18-month study.Scientific reports · 2025Article
- Biological Features, Antimicrobial Susceptibility and Phenotypic Characterization ofJournal of fungi (Basel, Switzerland) · 2025Article
- Octenidine effectively reduces Candida auris colonisation on human skin.Scientific reports · 2025Article
- Discrimination of Clinical and Food-DerivedPathogens (Basel, Switzerland) · 2025Article
- Candida auris cells form giant lipid droplets to survive in harsh environments.Communications biology · 2025Article
- Antifungal and Antioxidant Activity of Thiourea Derivatives Against NosocomialMolecules (Basel, Switzerland) · 2025Article
- Review
- Characterization of susceptibility patterns and adaptability of the newly emerged Candida auris.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Interactions of the emerging fungusMicrobiology spectrum · 2025Article
- Candidiasis: Insights into Virulence Factors, Complement Evasion and Antifungal Drug Resistance.Microorganisms · 2025Review
- New Evidence forPharmaceuticals (Basel, Switzerland) · 2025Article
- Emerging Fungal Infections of the Central Nervous System in the Past Decade: A Literature Review.Infectious disease reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.